Work

Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study

Year: 2016

Type: conference-abstract

Source: European Respiratory Journal

DOI: 10.1183/13993003.congress-2016.pa989

Authors: Jadwiga Wedzicha, Claus F. Vogelmeier, Tim Ayers, Angel FowlerTaylor, Chau Thach, Petter Olsson, Robert Fogel, Francesco Patalano, Donald Banerji

Institutions: Imperial College London, Universitätsklinikum Gießen und Marburg, Novartis (Switzerland), Novartis (United States)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2550392040

Cites:

Cited by:

Related to: 10